Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in New-Onset Type 1 Diabetes: A Multicenter Analysis
Francesca D'Addio,Francesca D'Addio,Alessandro Valderrama Vasquez,Moufida Ben Nasr,Edward Franek,Dalong Zhu,Lirong Li,Guang Ning,Emilian Snarski,Paolo Fiorina,Paolo Fiorina +10 more
TL;DR: This study suggests the following: 1) that remission of T1D is possible by combining HSC transplantation and immunosuppression; 2) that autologous nonmyeloablative H SC transplantation represents an effective treatment for selected individuals with T2D; and 3) that safer HSC-based therapeutic options are required.
read more
Abstract: Type 1 diabetes (T1D) is one of the major autoimmune diseases affecting children and young adults worldwide. To date, the different immunotherapies tested have achieved insulin independence in 1c levels and an increase in C-peptide levels compared with pretreatment. Despite a complete immune system recovery (i.e., leukocyte count) after treatment, 52% of treated individuals experienced adverse effects. Our study suggests the following: 1 ) that remission of T1D is possible by combining HSC transplantation and immunosuppression; 2 ) that autologous nonmyeloablative HSC transplantation represents an effective treatment for selected individuals with T1D; and 3 ) that safer HSC-based therapeutic options are required.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
•Journal Article
Application of Allotransplantation of Fetal Liver-derived Stem-Cells for Treatment of Type 1 Diabetes: a Single-arm, Phase 3 Clinical Trial
Ali Tootee,Ensieh Nasli Esfahani,Maryam Ghodsi,Farideh Razi,Mohammadreza Amini,Bagher Larijani,Ramin Heshmat +6 more
TL;DR: Assessment of the effectiveness of allotransplantation of fetal liver-derived fetal stem-cells for treatment of patients with type 1 diabetes found that stem-cell therapy resulted in significant changes in indicators of diabetes control and beta-cell function.
Immunomodulation Induced by Stem Cell Mobilization and Harvesting in Healthy Donors: Increased Systemic Osteopontin Levels after Treatment with Granulocyte Colony-Stimulating Factor.
Guro Kristin Melve,Elisabeth Ersvær,Cigdem Ahaein Akkøk,Aymen Bushra Ahmed,Einar K. Kristoffersen,Einar K. Kristoffersen,Tor Hervig,Tor Hervig,Øystein Bruserud +8 more
TL;DR: Peripheral blood stem cells from healthy donors mobilized by granulocyte colony-stimulating factor (G-CSF) and harvested by leukapheresis are commonly used for allogeneic stem cell transplantation, indicating mobilization-related immunoregulatory effects.
Autologous bone marrow stem cell transplantation for the treatment of ulcerative colitis complicated with herpes zoster: a case report
Hang Xiang,Xiao-Mei Zhang,Chao Yang,Wen-Huan Xu,Xin Ge,Rong Zhang,Ya Qiu,Wanjun Sun,Fan Li,Tianyuan Xiang,Haixu Chen,Zheng Wang,Qiang Zeng +12 more
TL;DR: After the patient underwent auto bone marrow mononuclear cells transplantations twice, the patient’s symptoms were alleviated, and he recovered from hematochezia, and his hypersensitive C reactive protein decreased.
5
Circulating Hematopoietic (HSC) and Very-Small Embryonic like (VSEL) Stem Cells in Newly Diagnosed Childhood Diabetes type 1 - Novel Parameters of Beta Cell Destruction/Regeneration Balance and Possible Prognostic Factors of Future Disease Course
Milena Jamiołkowska-Sztabkowska,Kamil Grubczak,Aleksandra Starosz,Anna Kretowska-Grunwald,Magdalena Krętowska,Zuzanna Parfienowicz,Marcin Moniuszko,Artur Bossowski,Barbara Głowińska-Olszewska +8 more
TL;DR: In this paper, the authors evaluated the role of very small embryonic-like stem cells (VSEL) mobilization in maintaining residual beta cell function in children newly diagnosed with Type 1 diabetes.
References
Type 1 Diabetes
TL;DR: Current progress in epidemiology, pathology, diagnosis, and treatment of type 1 diabetes, and prospects for an improved future for individuals with this disease are discussed.
2.3K
Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study
TL;DR: If present trends continue, doubling of new cases of type 1 diabetes in European children younger than 5 years is predicted between 2005 and 2020, and prevalent cases younger than 15 years will rise by 70%.
1.8K
Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial
Tihamer Orban,Brian N. Bundy,Dorothy J. Becker,Linda A. DiMeglio,Stephen E. Gitelman,Robin Goland,Peter A. Gottlieb,Carla J. Greenbaum,Jennifer B. Marks,Roshanak Monzavi,Antoinette Moran,Philip Raskin,Henry Rodriguez,William E. Russell,Desmond A. Schatz,Diane K. Wherrett,Darrell M. Wilson,Jeffrey P. Krischer,Jay S. Skyler +18 more
TL;DR: Abatacept (10 mg/kg, maximum 1000 mg per dose) or placebo infusions intravenously on days 1, 14, 28, and monthly for a total of 27 infusions over 2 years.
516
Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial.
Nicole A. Sherry,William Hagopian,Johnny Ludvigsson,Sunil M Jain,Jack Wahlen,Robert J. Ferry,Bruce W. Bode,S. Aronoff,Christopher Holland,David Carlin,Karen L King,Ronald L. Wilder,Stanley R. Pillemer,Ezio Bonvini,Syd Johnson,Kathryn E. Stein,Scott Koenig,Kevan C. Herold,Anastasia G. Daifotis +18 more
TL;DR: It is suggested that future studies of immunotherapeutic intervention with teplizumab might have increased success in prevention of a decline in β-cell function (measured by C-peptide) and provision of glycaemic control at reduced doses of insulin if they target patients early after diagnosis of diabetes and children.
473
Tolerance induction by "megadose" hematopoietic transplants: donor-type human CD34 stem cells induce potent specific reduction of host anti-donor cytotoxic T lymphocyte precursors in mixed lymphocyte culture.
Nurit Rachamim,Judith Gan,Harry Segall,Rita Krauthgamer,Hadar Marcus,Alain Berrebi,Massimo F. Martelli,Yair Reisner +7 more
TL;DR: It is possible, that CD34+ cells in the megadose transplants-perhaps by their inability to provide costimulatory molecules-are actively reducing the frequency of CTL-p directed against their antigens, and thereby help to overcome allogeneic rejection, and enhance their own engraftment.
195
Related Papers (5)
Nicole A. Sherry,William Hagopian,Johnny Ludvigsson,Sunil M Jain,Jack Wahlen,Robert J. Ferry,Bruce W. Bode,S. Aronoff,Christopher Holland,David Carlin,Karen L King,Ronald L. Wilder,Stanley R. Pillemer,Ezio Bonvini,Syd Johnson,Kathryn E. Stein,Scott Koenig,Kevan C. Herold,Anastasia G. Daifotis +18 more
Bart Keymeulen,Evy Vandemeulebroucke,Anette-G. Ziegler,Chantal Mathieu,Leonard Kaufman,Geoff Hale,Frans Gorus,Michel Goldman,M Walter,Sophie Candon,Liliane Schandené,Laurent Crenier,Christophe De Block,Jean-Marie Seigneurin,Pieter De Pauw,Denis Pierard,Ilse Weets,Peppy Rebello,Pru Bird,Eleanor Berrie,Mark Frewin,Herman Waldmann,Jean-François Bach,Daniel Pipeleers,Lucienne Chatenoud +24 more